A Monash University-led study has found that an unusual pairing of two commonly used antibiotics can kill and stop the spread of resistance in a highly drug-resistant bacterium, Pseudomonas aeruginosa, which can cause life-threatening bloodstream infections, pneumonia and meningitis.

Published in The Lancet Microbe, Monash Institute of Pharmaceutical Sciences (MIPS) researchers used a validated laboratory infection system in which they were able to expose bacterial samples from infected patients to simulated antibiotic dosing regimens, as would actually occur in hospitalised patients.

Cholesterol-related heart disease remains the leading cause of death worldwide, and while doctors have more tools than ever to treat it, many patients still can't achieve safe cholesterol levels, or can't tolerate the side effects of available medications. Now, researchers from University of California San Diego School of Medicine have uncovered a hidden biological pathway that explains why high-cholesterol diets steadily chip away at our body's ability to clear harmful low-density lipoprotein (LDL) cholesterol from the blood,

Developing new medicines can require thousands of chemistry experiments to identify the right recipe for a safe, effective and ideally affordable drug.

The process is slow and labor-intensive, and many of the reactions depend on hard-to-source metals that act as essential catalysts.

Researchers at the UCLA Health Jonsson Comprehensive Cancer Center have developed a new platform that combines 3D bioprinting, advanced imaging and artificial intelligence to better monitor how cancer responds to treatment. The technology could help researchers identify promising cancer therapies more rapidly and provide a way to test treatments on a patient's own tumor cells, helping guide more personalized treatment decisions.

For the 18 million people living with rheumatoid arthritis, disease management currently means a lifetime of injections - a reality that new research from Tsinghua University may soon begin to change. Current first-line biologics targeting tumor necrosis factor (TNF) - including adalimumab (Humira), long among the world’s best-selling drugs - require injections every two weeks, potentially for decades. Prolonged use drives anti-drug antibody (ADA) formation in many patients, eroding therapeutic benefit and causing secondary treatment failure.

New antibiotic candidates for drug-resistant bacteria may reside inside prions, mis-folded protein in the brain best known for rare and fatal degenerative brain diseases. Prion and prion-like proteins may hide short peptides, named “prionins,” that can kill bacteria, suggesting proteins best known for their role in neurodegeneration may contain molecular features linked to immune defense, according to new research from the Perelman School of Medicine at the University of Pennsylvania.

For some people, cancer immunotherapies are life-changing. These treatments can turn the body’s own immune system against a tumor, either eliminating it or shrinking it enough to make surgery possible. But these therapies don’t work for everyone, can gradually stop working or can come with a host of side effects, including severe inflammation.